Can you discuss the gross margin progression, where it can go, and the levers available to manage inflationary pressures?

Management highlighted that product mix with higher standard margins, integration synergies from Lima, and continuous improvement initiatives are driving gross margin expansion. They expect a multi-year cadence of margin expansion, actively offsetting inflationary pressures. “We see a multi-year cadence of margin expansion and a lot of that driven by gross margins.”

What are the key drivers to achieve 40-50% and then 70-80% free cash flow conversion, especially as integration costs subside?

Management stated that adjusted costs from the Lima integration are stepping down and will continue to do so. Productivity in working capital, driven by realigned incentives and the EGX toolkit, is also a key driver. They noted the first half was positive FCF and expect stronger cash generation in the second half. “I mean, I think you're really starting to see adjusted costs start to step down like we've talked about. You know, we're in year three of a pretty complex integration of a European asset in Lima, and we'll expect that to continue to step down even as we enter into next year.”

Are the softer European market comments due to transient strikes or a more concerning slowing demand trend?

Management believes the softness in Western Europe (France, Spain, Italy) is primarily due to transient factors like strikes, fires, and heat waves, which delay rather than eliminate procedures. The main watch-out is the potential reorientation of funding from healthcare to military due to the Middle East conflict, though no read-through has been seen yet. “I would say it's more weighted to the transient. So, you know, again, strikes, fires, heat waves, you know, all of those things we believe are transient and ultimately, you know, you keep the patient in the funnel, it's just you delay the procedure.”

ENOV

Enovis (ENOV) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Enovis Q2 FY26 — Strong Organic Growth and Margin Expansion Despite Headwinds

Enovis delivered robust Q2 FY26 results, driven by strong organic growth in Recon and P&R segments, alongside significant adjusted gross margin expansion. The company reaffirmed its full-year guidance, navigating headwinds from international conflicts and inflation through operational productivity and new product scaling. Management emphasized continued focus on commercial execution, innovation, and financial discipline, including debt reduction and free cash flow generation, while evaluating future portfolio advancements.

Highlights

Delivered 5% organic growth company-wide in Q2 FY26.
US Recon segment grew 6% organically in Q2 FY26, led by 8% organic growth in hips and knees.
Adjusted gross margins expanded to 62% in Q2 FY26, an underlying improvement of 120 basis points.
Adjusted earnings per share reached $0.90, representing 14% underlying growth in Q2 FY26.
Free cash flow improved by $27 million year-over-year to $31 million in Q2 FY26.

Concerns

International business negatively impacted by Middle East conflict, resulting in a 100 basis point headwind to international growth and 40 basis points to total company growth in Q2 FY26.
Experienced $4 million of ongoing tariff impact and $2 million of unplanned inflationary pressure in Q2 FY26.
Expect a $10 million full-year impact from the increased inflationary environment in FY26.
Noted softer markets in Western Europe (France, Spain, Italy) due to environmental factors in Q2 FY26.
Anticipate Q3 FY26 to have a heavier impact by seasonality than in prior years due to market conditions and Middle East conflict.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Guidance	Reaffirmed high materiality	FY26	High
Free Cash Flow Conversion	greater than 25% high materiality	FY26	High
Q3 Seasonality Impact	heavier impact by seasonality than in prior years medium materiality	Q3 · FY26	Medium
Q4 Sales Acceleration	sales acceleration across both segments medium materiality	Q4 · FY26	Medium
Leverage Ratio	below 3x high materiality	FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Recon Strong performance driven by hips and knees in the US and double-digit growth in international shoulders. Nebula and Arvis are key growth drivers. US Recon organic growth: 6%Hips and Knees organic growth: 8%International Recon organic growth: 6%Shoulders growth: double-digitNebula new instrumentation sets to competitive users: >80%Arvis: full commercial launch in US	—	6% organic	—	—
P&R Growth driven by global bracing and strong performance in Recovery Sciences and Bone Stim. New products are expected to contribute more in the latter part of the year. Global Bracing growth: 4%US Bracing growth: mid-single-digitRecovery Sciences and Bone Stim growth: mid-to-high single-digit	—	3% organic	—	—

Product announcements

Product	Type	Timeline	Details
Arvis	launch	Q2 FY26
Revital treatment	launch	later part of the year

Deals & partnerships

Dr. Comfort Divestiture of the Dr. Comfort business.

The divestiture of Dr. Comfort resulted in a headwind to reported growth for the quarter, reflecting a strategic shaping of the portfolio.

Risks & headwinds

Middle East conflict impact on international business Q2 FY26, ongoing

100 bps headwind to international recon growth, 40 bps headwind to total company growth in Q2 FY26.

Mitigation:Focus on commercial execution, account conversions, and market share gains to get ahead of potential impacts. Monitoring potential reorientation of funding towards military spend versus healthcare.

Ongoing tariff impact Q2 FY26, ongoing

$4 million in Q2 FY26.

Mitigation:Actively working to mitigate, but balancing price increases with potential revenue risk, especially in the P&R business.

Unplanned inflationary pressure Q2 FY26, full-year FY26

$2 million in Q2 FY26, expected $10 million full-year impact for FY26.

Mitigation:Implementing mitigation efforts, trying to pass through price increases where possible, focusing on productivity.

Softer markets in Western Europe Q2 FY26, potentially ongoing

Not quantified, described as 'slightly softer market' in France, Spain, Italy.

Mitigation:Believed to be transient (strikes, fires, heat waves) causing delays in procedures rather than cancellations. Focusing on commercial execution and market share gains.

Increased seasonality impact in Q3 Q3 FY26

Heavier impact by seasonality than in prior years.

Mitigation:Offsetting with benefits from commercial execution, new product scaling, and continued penetration of Nebula and ARG.

US market noise from policy proposals Ongoing

Not quantified, described as 'some noise'.

Mitigation:Monitoring physician payment proposals and CJRX, but overall US markets are seen as stable.

What to watch in Q3 FY26

Q3 Seasonality Impact on Sales

next quarter

Current Expected to be heavier than prior years

Target Actual impact on Q3 sales growth

Why it matters

This will indicate the effectiveness of mitigation strategies against market conditions in Western Europe and the Middle East conflict.

In terms of quarterly phasing for the second half, we expect the third quarter to have a heavier impact by seasonality than in prior years due to market conditions in Western Europe and the continued disruption from the conflicts in the Middle East.

Find out whether ENOV delivers this. Inve re-checks your case every morning.

Q&A highlights

Can you elaborate on the dynamics in US Recon, particularly the softer extremities growth in Q2 compared to hips and knees, and expectations for the rest of the year?

Management clarified that H1 extremities growth was strong at 8%, similar to hips and knees. Q2 softness was attributed to a tough comp from the prior year's ARG launch and numerous medical education events that took high-volume surgeons out of the market. They expect continued momentum in H2 with ARG and Arvis expansion.

“The Q2, yes, we had some challenges there with a few things. One is we're lapping the ARG launch from last year. So it was a pretty tough comp. But I think importantly, we had a lot of med ed events in Q2 that took a lot of our high volume KOLs and surgeons out of the space for a few weeks.”

asked by Ryan Zimmerman · answered by Unknown Speaker

2 min read 6 chapters

Detailed narrative

Q2 Performance and Segment Drivers

Enovis delivered 5% organic growth in Q2 FY26, with reported sales of $583 million. The Recon segment led with 6% organic growth, driven by strong performance in US hips and knees (8% organic growth) and international shoulders (double-digit growth). The P&R segment grew 3% organically, supported by global bracing (4% growth) and mid-to-high single-digit growth in Recovery Sciences and Bone Stim.

The company noted a 4% days-adjusted organic growth at the enterprise level.

Innovation and Product Momentum

Innovation remains a core pillar, with Nebula continuing to drive growth in hips and knees, with over 80% of new instrumentation sets going to competitive users. The Arvis platform moved into full commercial launch in the US in Q2, receiving positive early feedback for its versatility and suitability for complex shoulder anatomy.

New products in P&R, including the Revital treatment in the companion market, are expected to contribute more significantly in the latter half of the year, supporting continued market share gains.

Operational Excellence and Margin Expansion

Adjusted gross margins improved by 120 basis points underlying to 62% in Q2, benefiting from an $8 million tariff refund and operational productivity. Adjusted EBITDA margin improved by 70 basis points underlying to 17.9%. The company is focused on optimizing its operating model through initiatives like EGX and consolidating production facilities in lower-cost locations, expecting multi-year margin expansion.

Investments in R&D have also stepped up to support future growth.

Financial Discipline and Capital Allocation

Enovis has made significant progress in financial discipline, moving from negative to positive free cash flow in the first half of FY26, with Q2 FCF at $31 million. Leverage has been reduced to 3.1 times, and the balance sheet refinanced.

The company aims to bring leverage below 3x by year-end. With the Lima integration costs stepping down, Enovis is beginning to evaluate portfolio advancements for long-term growth while maintaining focus on cash generation and debt reduction, including potential divestitures and SKU reductions.

Market Dynamics and Headwinds

The company faced several headwinds, including a 40 basis point impact to total growth from the Middle East conflict and softer markets in Western Europe (France, Spain, Italy) due to transient environmental factors. Unplanned inflationary pressures, totaling $2 million in Q2 and an expected $10 million for the full year, are being actively mitigated.

Despite these, the US ortho market remains stable, though with week-to-week volatility, and the company is confident in its ability to gain share.

ASC Strategy and Competitive Landscape

Enovis views the ASC setting as a significant advantage due to patient and physician preference, favorable reimbursement dynamics, and opportunities for market share gains where contracts are less fixed. Products like Arvis are particularly well-suited for ASCs due to their mobility and economics. The company sees opportunities to attract talent and gain share amidst competitors experiencing disruption, leveraging its stable growth and nimble innovation.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.